期刊
EXPERT OPINION ON DRUG SAFETY
卷 20, 期 4, 页码 387-396出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14740338.2021.1893303
关键词
Emicizumab; hemophilia A; monoclonal antibody; factor; prophylaxis
Emicizumab is an effective alternative to prophylaxis with factor VIII replacement in individuals with hemophilia A, showing improved outcomes in reducing bleeding events. Despite a few cases of thrombotic microangiopathy and thrombotic events seen in the HAVEN 1 trial, overall, Emicizumab has an excellent safety profile with minimal side effects.
Introduction Emicizumab is a bispecific-humanized monoclonal antibody that improves hemostasis by bridging activated factor IX and factor X to substitute for the function of missing activated FVIII. It is an alternative to prophylaxis with factor VIII replacement and is associated with improved outcomes in individuals with hemophilia A with and without inhibitors. Areas covered Emicizumab is efficacious in reducing bleeding events when compared to on-demand treatment and factor-based prophylaxis. Except for the few thrombotic microangiopathy and thrombotic event cases mainly seen in the HAVEN 1 trial, emicizumab has an overall excellent safety profile with minimal side effects. Expert opinion Knowledge gaps include the efficacy and safety of emicizumab in younger age groups and those with mild or moderate hemophilia A. Future directions for research include exploring the risk of inhibitor recurrence in patients with a history of high titer inhibitor who have been successfully tolerized, who switch from factor prophylaxis to emicizumab, as well as conducting 'real world studies' to evaluate the patient's perception of emicizumab in regard to ease and tolerability in order to optimize individualized treatment plans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据